ConductScience.org, home

Paper35840720

Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.

Baxi V and 17 others. Mod Pathol, 2022. Cited by 52 papers, by iCite.

Cite this record

ConductScience Library. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab. Papers, record 35840720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35840720

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
PubMed
Journal
Mod Pathol
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
52
iCite
Relative citation ratio, by iCite
3.91
iCite
Revised in PubMed
2023-02-10
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baxi VVipul
2Lee GGeorgehttps://orcid.org/0000-0002-8705-9210
3Duan CChunzhe
4Pandya DDimple
5Cohen DNDaniel N
6Edwards RRobin
7Chang HHan
8Li JJun
9Elliott HHunter
10Pokkalla HHarsha
11Glass BBenjamin
12Agrawal NNishant
13Lahiri AAbhik
14Wang DDayong
15Khosla AAditya
16Wapinski IIlan
17Beck AAndrew
18Montalto MMichael

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Carcinoma, Transitional CellMajor topic
Lung NeoplasmsMajor topic
Urinary Bladder NeoplasmsMajor topic
Humans
B7-H1 Antigen
Nivolumab
Ipilimumab
Artificial Intelligence
Retrospective Studies
Antibodies, Monoclonal
Biomarkers, Tumor

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130345906Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.N Engl J Med2018https://conductscience.org/library/papers/30345906PubMed
231656061Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.J Pathol Transl Med2019https://conductscience.org/library/papers/31656061PubMed
326712084Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet2016https://conductscience.org/library/papers/26712084PubMed
426317305Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.Appl Immunohistochem Mol Morphol2015https://conductscience.org/library/papers/26317305PubMed
528131785Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.Lancet Oncol2017https://conductscience.org/library/papers/28131785PubMed
631463730PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.Virchows Arch2020https://conductscience.org/library/papers/31463730PubMed
728891423Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.N Engl J Med2017https://conductscience.org/library/papers/28891423PubMed
830478349Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.Sci Rep2018https://conductscience.org/library/papers/30478349PubMed
931399699Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology.Nat Rev Clin Oncol2019https://conductscience.org/library/papers/31399699PubMed
1026412456Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.N Engl J Med2015https://conductscience.org/library/papers/26412456PubMed
1126994219Multispectral Imaging of T and B Cells in Murine Spleen and Tumor.J Immunol2016https://conductscience.org/library/papers/26994219PubMed
1231060602Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.J Immunother Cancer2019https://conductscience.org/library/papers/31060602PubMed
1324872352Fully non-parametric receiver operating characteristic curve estimation for random-effects meta-analysis.Stat Methods Med Res2017https://conductscience.org/library/papers/24872352PubMed
1430470933Precision immunoprofiling by image analysis and artificial intelligence.Virchows Arch2019https://conductscience.org/library/papers/30470933PubMed
1530955977
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet2019https://conductscience.org/library/papers/30955977PubMed
1627718784Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.N Engl J Med2016https://conductscience.org/library/papers/27718784PubMed
1732300181Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.Mod Pathol2020https://conductscience.org/library/papers/32300181PubMed
1828664936PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.Mod Pathol2017https://conductscience.org/library/papers/28664936PubMed
1928420726Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.Clin Cancer Res2017https://conductscience.org/library/papers/28420726PubMed
2031562797Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2019https://conductscience.org/library/papers/31562797PubMed

See all 35 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.

PMIDTitleJournalYearIn PapersSource
42606343Inter-Rater Agreement in PD-L1 (22C3) Expression Evaluation in Colon Cancer.Appl Immunohistochem Mol Morphol2026https://conductscience.org/library/papers/42606343PubMed
42443785Unlocking the prognostic power of pathomics in bladder cancer: a machine learning odyssey across multiple centers.BMC Med Imaging2026https://conductscience.org/library/papers/42443785PubMed
42279570Artificial Intelligence in Dermatopathology: An Update and Review of the Current Literature.Diagnostics (Basel)2026https://conductscience.org/library/papers/42279570PubMed
42147747Advancements in Image-Based Artificial Intelligence in the Diagnosis and Treatment of Head and Neck Squamous Cell Carcinoma: A Narrative Review.Int J Gen Med2026https://conductscience.org/library/papers/42147747PubMed
41976406Integrating Artificial Intelligence into Breast Cancer Histopathology: Toward Improved Diagnosis and Prognosis.Cancers (Basel)2026https://conductscience.org/library/papers/41976406PubMed
41961172Medical biotechnology and artificial intelligence powered companion diagnostics: indispensable pillars driving next generation precision health care.Biotechnol Lett2026https://conductscience.org/library/papers/41961172PubMed
41867453Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer.J Inflamm Res2026https://conductscience.org/library/papers/41867453PubMed
41754942Artificial Intelligence in Lung Cancer: A Narrative Review of Recent Advances in Diagnosis, Biomarker Discovery, and Drug Development.Pharmaceutics2026https://conductscience.org/library/papers/41754942PubMed
41631127Applications and challenges of utilizing digital pathology and AI-enabled workflows in clinical trials.J Pathol Inform2026https://conductscience.org/library/papers/41631127PubMed
41590351Machine Learning in Biomarker-Driven Precision Oncology: Automated Immunohistochemistry Scoring and Emerging Directions in Genitourinary Cancers.Curr Oncol2026https://conductscience.org/library/papers/41590351PubMed
41340634Predicability of PD-L1 expression in cancer cells based solely on H&E-stained sections.J Pathol Inform2025https://conductscience.org/library/papers/41340634PubMed
41316486The role of artificial intelligence-based foundation models and "copilots" in cancer pathology: potential and challenges.J Exp Clin Cancer Res2025https://conductscience.org/library/papers/41316486PubMed
40968169Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.NPJ Precis Oncol2025https://conductscience.org/library/papers/40968169PubMed
40867268Immune Biomarkers for Checkpoint Blockade in Solid Tumors: Transitioning from Tissue to Peripheral Blood Monitoring and Future Integrated Strategies.Cancers (Basel)2025https://conductscience.org/library/papers/40867268PubMed
40750675Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer.Commun Med (Lond)2025https://conductscience.org/library/papers/40750675PubMed
40305346Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment.Biomolecules2025https://conductscience.org/library/papers/40305346PubMed
40243442Double-Multiplex Immunostainings for Immune Profiling of Invasive Breast Carcinoma: Emerging Novel Immune-Based Biomarkers.Int J Mol Sci2025https://conductscience.org/library/papers/40243442PubMed
40189932PD-L1 Scoring Models for Non-Small Cell Lung Cancer in China: Current Status, AI-Assisted Solutions and Future Perspectives.Thorac Cancer2025https://conductscience.org/library/papers/40189932PubMed
40075729A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/40075729PubMed
39979258Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts.Nat Commun2025https://conductscience.org/library/papers/39979258PubMed

See all 32 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
SRPRA6734PubTator's text mininghttps://conductscience.org/library/genes/6734NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35840720

GET https://conductscience.org/api/papers/v1/35840720/references?page=2